Phase 3 study of Levadex for the treatment of migraines
MAP Pharmaceuticals announced that the efficacy portion of its first Phase 3 trial evaluating its novel migraine therapy, Levadex (dihydroergotamine (DHE)), met all four primary endpoints.
MAP Pharmaceuticals announced that the efficacy portion of its first Phase 3 trial evaluating its novel migraine therapy, Levadex (dihydroergotamine (DHE)), met all four primary endpoints.
